5-[4-(三氟甲基)苯基]-1,2-恶唑-3-羧酸 | 668970-85-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 5-[4-(三氟甲基)苯基]-1,2-恶唑-3-羧酸
• 英文名称: 5-(4-trifluoromethylphenyl)isoxazole-3-carboxylic acid
• 英文别名: 5-[4-(Trifluoromethyl)phenyl]-1,2-oxazole-3-carboxylic acid
• CAS: 668970-85-2
• 化学式: C₁₁H₆F₃NO₃
• mdl: MFCD07377112
• 分子量: 257.169
• InChiKey: RILMWGDLHDRILD-UHFFFAOYSA-N

物化性质

• 沸点：
  403.4±45.0 °C(Predicted)
• 密度：
  1.454±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  63.3
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  5-[4-(三氟甲基)苯基]-1,2-恶唑-3-羧酸 、 3-苯基-1-丙胺 在 1-羟基苯并三唑 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 24.75h， 以55%的产率得到5-(4-(trifluoromethyl)phenyl)-N-(3-phenylpropyl)isoxazole-3-carboxamide
  参考文献：
  名称：

  New FAAH inhibitors based on 3-carboxamido-5-aryl-isoxazole scaffold that protect against experimental colitis

  摘要：

  Growing evidence suggests a role for the endocannabinoid (EC) system, in intestinal inflammation and compounds inhibiting anandamide degradation offer a promising therapeutic option for the treatment of inflammatory bowel diseases. In this paper, we report the first series of carboxamides derivatives possessing FAAH inhibitory activities. Among them, compound 39 displayed significant inhibitory FAAH activity (IC50 = 0.088 mu M) and reduced colitis induced by intrarectal administration of TNBS. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.04.057
• 作为产物：
  描述：

  ethyl 2-hydroxy-4-oxo-4-(4-trifluoromethyl-phenyl)-but-2-enoate 在 盐酸羟胺 、 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 26.0h， 生成 5-[4-(三氟甲基)苯基]-1,2-恶唑-3-羧酸
  参考文献：
  名称：

  New FAAH inhibitors based on 3-carboxamido-5-aryl-isoxazole scaffold that protect against experimental colitis

  摘要：

  Growing evidence suggests a role for the endocannabinoid (EC) system, in intestinal inflammation and compounds inhibiting anandamide degradation offer a promising therapeutic option for the treatment of inflammatory bowel diseases. In this paper, we report the first series of carboxamides derivatives possessing FAAH inhibitory activities. Among them, compound 39 displayed significant inhibitory FAAH activity (IC50 = 0.088 mu M) and reduced colitis induced by intrarectal administration of TNBS. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.04.057

文献信息

• [EN] ANTIBACTERIAL BENZOIC ACID DERIVATIVES<br/>[FR] DERIVES D'ACIDES BENZOIQUES ANTIBACTERIENS
  申请人：UPJOHN CO

  公开号：WO2004018428A1

  公开（公告）日：2004-03-04

  The invention provides antimicrobial agents and methods of using the agents for sterilization, sanitation, antisepsis, disinfection, and treatment of infections in mammals.

  这项发明提供了抗菌剂和使用这些剂进行哺乳动物的消毒、卫生、防腐、消毒和治疗感染的方法。
• [EN] PIPERIDINE CXCR7 RECEPTOR MODULATORS<br/>[FR] MODULATEURS DU RÉCEPTEUR DE CXCR7 PIPÉRIDINE
  申请人：IDORSIA PHARMACEUTICALS LTD

  公开号：WO2018019929A1

  公开（公告）日：2018-02-01

  The present invention relates to piperidine derivatives of formula (I) wherein Ar1, Ar2, RAr1, R1, R2, and R3 are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.

  本发明涉及式(I)的哌啶衍生物，其中Ar1、Ar2、RAr1、R1、R2和R3如描述中所述，它们的制备，其药学上可接受的盐，以及它们作为药物的用途，含有一个或多个式(I)化合物的药物组合物，特别是它们作为CXCR7受体调节剂的用途。
• Isoxazole Derivatives and Use Thereof
  申请人：Cho Jeong Woo

  公开号：US20090131336A1

  公开（公告）日：2009-05-21

  Disclosed herein are isoxazole derivaties and uses thereof. Serving as agonists of Wnt, the isoxazole derivatives activate Wnt/β-catenin signaling and thus can be used in the treatment and prevention of diseases related to the signal transduction. Also, pharmaceutically acceptable salts of the isoxazole derivatives are disclosed.

  本文披露了异噁唑衍生物及其用途。作为Wnt的激动剂，异噁唑衍生物激活Wnt/β-连环蛋白信号传导，因此可用于治疗和预防与信号传导相关的疾病。此外，还披露了异噁唑衍生物的药用盐。
• Antibacterial benzoic acid derivatives
  申请人：——

  公开号：US20040110802A1

  公开（公告）日：2004-06-10

  The invention provides antimicrobial agents and methods of using the agents for sterilization, sanitation, antisepsis, disinfection, and treatment of infections in mammals.

  这项发明提供了抗微生物药剂及其使用方法，用于哺乳动物的消毒、卫生、防腐、消毒和治疗感染。
• COMPOUNDS
  申请人：SOFIA MICHAEL JOSEPH

  公开号：US20120202794A1

  公开（公告）日：2012-08-09

  Disclosed herein are compounds useful for treating a viral infection, such as HCV.

  本文公开了用于治疗病毒感染，如HCV的化合物。